DE60229041D1 - Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen - Google Patents

Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen

Info

Publication number
DE60229041D1
DE60229041D1 DE60229041T DE60229041T DE60229041D1 DE 60229041 D1 DE60229041 D1 DE 60229041D1 DE 60229041 T DE60229041 T DE 60229041T DE 60229041 T DE60229041 T DE 60229041T DE 60229041 D1 DE60229041 D1 DE 60229041D1
Authority
DE
Germany
Prior art keywords
nicotinic acid
leptin
mirrors
increasing
acid compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60229041T
Other languages
German (de)
English (en)
Inventor
Elaine Jacobson
Myron K Jacobson
Hyuntae Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
University of Arizona
Original Assignee
University of Kentucky Research Foundation
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23047813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60229041(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Kentucky Research Foundation, University of Arizona filed Critical University of Kentucky Research Foundation
Application granted granted Critical
Publication of DE60229041D1 publication Critical patent/DE60229041D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60229041T 2001-03-08 2002-03-08 Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen Expired - Lifetime DE60229041D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27434901P 2001-03-08 2001-03-08
PCT/US2002/007256 WO2002072092A1 (en) 2001-03-08 2002-03-08 Method for increasing leptin levels using nicotinic acid compounds

Publications (1)

Publication Number Publication Date
DE60229041D1 true DE60229041D1 (de) 2008-11-06

Family

ID=23047813

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229041T Expired - Lifetime DE60229041D1 (de) 2001-03-08 2002-03-08 Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen

Country Status (12)

Country Link
US (2) US6750234B2 (enExample)
EP (1) EP1365762B1 (enExample)
JP (1) JP5057353B2 (enExample)
CN (1) CN1265792C (enExample)
AT (1) ATE409037T1 (enExample)
CA (1) CA2437844C (enExample)
DE (1) DE60229041D1 (enExample)
DK (1) DK1365762T3 (enExample)
ES (1) ES2315358T3 (enExample)
MX (1) MXPA03008096A (enExample)
PT (1) PT1365762E (enExample)
WO (1) WO2002072092A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
WO2002009639A2 (en) 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
DK1365762T3 (da) * 2001-03-08 2008-11-17 Univ Kentucky Res Found Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser
KR101188292B1 (ko) * 2002-11-27 2012-10-09 디엠아이 바이오사이언시스, 인크 인산화 증가로 인한 질병 및 증상의 치료방법
US7736636B2 (en) * 2003-02-12 2010-06-15 Shaker Mousa Method for treating occlusive vascular diseases & wound healing
US8811348B2 (en) 2003-02-24 2014-08-19 Qualcomm Incorporated Methods and apparatus for generating, communicating, and/or using information relating to self-noise
US7218948B2 (en) 2003-02-24 2007-05-15 Qualcomm Incorporated Method of transmitting pilot tones in a multi-sector cell, including null pilot tones, for generating channel quality indicators
US8514692B2 (en) 2003-02-24 2013-08-20 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information which can be used for interference control purposes
US9544860B2 (en) 2003-02-24 2017-01-10 Qualcomm Incorporated Pilot signals for use in multi-sector cells
DK1651161T3 (da) 2003-08-07 2012-01-30 Healor Ltd Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US8503938B2 (en) 2004-10-14 2013-08-06 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information including loading factors which can be used for interference control purposes
JP2006253769A (ja) * 2005-03-08 2006-09-21 National Institute Of Advanced Industrial & Technology 情報処理システムおよび方法
RU2381786C2 (ru) * 2005-06-24 2010-02-20 Аризона Борд Оф Риджентс Он Бихаф Оф Дзе Юниверсити Оф Аризона Способ лечения нарушений роста волос, таких как облысение по женскому типу, и применяемые в нем композиции
EP1940440A4 (en) 2005-08-29 2009-11-11 Healor Ltd METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETIC AND AGED SKIN
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US8989084B2 (en) 2005-10-14 2015-03-24 Qualcomm Incorporated Methods and apparatus for broadcasting loading information corresponding to neighboring base stations
US9191840B2 (en) 2005-10-14 2015-11-17 Qualcomm Incorporated Methods and apparatus for determining, communicating and using information which can be used for interference control
US9473265B2 (en) 2005-12-22 2016-10-18 Qualcomm Incorporated Methods and apparatus for communicating information utilizing a plurality of dictionaries
US9125092B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus for reporting and/or using control information
US9137072B2 (en) 2005-12-22 2015-09-15 Qualcomm Incorporated Methods and apparatus for communicating control information
US9125093B2 (en) 2005-12-22 2015-09-01 Qualcomm Incorporated Methods and apparatus related to custom control channel reporting formats
US20070253449A1 (en) 2005-12-22 2007-11-01 Arnab Das Methods and apparatus related to determining, communicating, and/or using delay information
US8514771B2 (en) 2005-12-22 2013-08-20 Qualcomm Incorporated Methods and apparatus for communicating and/or using transmission power information
US7801589B2 (en) 2005-12-22 2010-09-21 Olympus Corporation In-vivo examination method and in-vivo examination apparatus
US9572179B2 (en) 2005-12-22 2017-02-14 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US9451491B2 (en) 2005-12-22 2016-09-20 Qualcomm Incorporated Methods and apparatus relating to generating and transmitting initial and additional control information report sets in a wireless system
US9119220B2 (en) 2005-12-22 2015-08-25 Qualcomm Incorporated Methods and apparatus for communicating backlog related information
US8437251B2 (en) 2005-12-22 2013-05-07 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
US9148795B2 (en) 2005-12-22 2015-09-29 Qualcomm Incorporated Methods and apparatus for flexible reporting of control information
US9338767B2 (en) 2005-12-22 2016-05-10 Qualcomm Incorporated Methods and apparatus of implementing and/or using a dedicated control channel
US20070243882A1 (en) 2006-04-12 2007-10-18 Qualcomm Incorporated Method and apparatus for locating a wireless local area network associated with a wireless wide area network
WO2008026349A1 (fr) * 2006-08-31 2008-03-06 Juridical Foundation Osaka Industrial Promotion Organization Agent thérapeutique destiné au traitement de l'effluvium télogène
NZ579416A (en) * 2007-02-28 2011-07-29 Univ Kentucky Res Found Method for reducing side effects of retinoic acid therapy by administration of a nicotinic acid alkyl ester such as myristyl nicotinate or palmitoyl nicotinate
AU2011204425A1 (en) 2010-01-11 2012-08-02 Healor Ltd. Method for treatment of inflammatory disease and disorder
CN118873522A (zh) * 2016-04-22 2024-11-01 无锡杰西医药股份有限公司 异硫氰酸酯类化合物的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505896A (en) * 1979-04-19 1985-03-19 Elorac, Ltd. Method of treating acne vulgaris and composition
DE3110611A1 (de) * 1981-03-18 1982-10-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "mitogene der leukozyten und des entzuendungsgewebes:natuerliche leukopoetine zur selektiven anregung der teilung und differenzierung von leukozyten"
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
EP0182635B1 (en) * 1984-11-15 1989-05-31 Nitto Denko Corporation Composition for percutaneous administration
US4965252A (en) * 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
JP2657583B2 (ja) * 1991-03-01 1997-09-24 ユニバーシテイ オブ フロリダ リサーチ ファンデーション インコーポレイテッド 神経系変性疾患の治療に対するニコチン類似体の利用
US5240945A (en) * 1992-02-18 1993-08-31 Warshaw Thelma G Method and compositions for treating acne
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
US5612382A (en) * 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
EP0815230A2 (en) * 1995-03-20 1998-01-07 Ligand Pharmaceuticals, Inc. MODULATORS OF ob GENE AND SCREENING METHODS THEREFOR
PT823897E (pt) * 1995-05-01 2004-11-30 Scarista Ltd Esteres de acido nicotico e composicoes farmaceuticas que os contem
US20040102358A1 (en) * 1997-05-19 2004-05-27 Scivoletto Rosemarie Composition for treating skin conditions
AU4672199A (en) * 1998-05-20 1999-12-06 Yale University Modulation of angiogenesis and wound healing
EP1143954B1 (en) * 1998-12-01 2004-08-11 University of Kentucky Research Foundation Use of nicotinic acid derivatives for the treatment of dna damage in skin cells
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
US6326034B1 (en) * 1999-12-22 2001-12-04 Natural Compounds Ltd Natural extracted and synthetic antioxidant compositions
DK1365762T3 (da) * 2001-03-08 2008-11-17 Univ Kentucky Res Found Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser

Also Published As

Publication number Publication date
US20040198776A1 (en) 2004-10-07
ES2315358T3 (es) 2009-04-01
EP1365762B1 (en) 2008-09-24
ATE409037T1 (de) 2008-10-15
WO2002072092A1 (en) 2002-09-19
CA2437844A1 (en) 2002-09-19
MXPA03008096A (es) 2005-10-05
PT1365762E (pt) 2008-11-27
CN1265792C (zh) 2006-07-26
JP2004519488A (ja) 2004-07-02
CA2437844C (en) 2007-05-15
JP5057353B2 (ja) 2012-10-24
CN1496260A (zh) 2004-05-12
DK1365762T3 (da) 2008-11-17
US6750234B2 (en) 2004-06-15
US20020128298A1 (en) 2002-09-12
EP1365762A4 (en) 2005-05-25
EP1365762A1 (en) 2003-12-03
HK1065941A1 (en) 2005-03-11

Similar Documents

Publication Publication Date Title
DE60229041D1 (de) Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
DE69936102D1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE327753T1 (de) Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
DE60335957D1 (de) Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
ATE369845T1 (de) Behandlung der nebenwirkungen von statinen
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
EP0948327A4 (en) ANTIDIABETIC AGENTS
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
ATE444749T1 (de) Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen
ATE262330T1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE60237594D1 (de) Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
DE602004016841D1 (de) Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen
DE602004014140D1 (de) Verfahren zur behandlung von alkoholischer hepatitis
ATE357915T1 (de) Verwendung von hydroxypyridon derivaten zur wundheilung
DE60305727D1 (de) Hypoestoxide, derivate und agonisten davon zur verwendung bei der behandlung und prophylaxe von hyperlipidämie
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
DE60313344D1 (de) Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition